Eric M Kraus

January 29, 2024 | New York Law Journal

On Dec. 12, 2023, MAPS PBC, now Lykos Therapeutics, announced their submission of a New Drug Application to the FDA for MDMA in combination with psychotherapy for the treatment of post-traumatic stress disorder.

By Lisa L. Smith, Eric M. Kraus and Julia M. Markov

7 minute read

September 15, 2022 | New York Law Journal

A recent decision from the Third Circuit limiting the extent to which district courts may condition FNC dismissals raises the question of whether the Second Circuit would impose similar limits.

By Eric M. Kraus, Joshua Glasgow and Shengkai Xu

8 minute read

May 09, 2022 | New York Law Journal

A recent decision out of the Ninth Circuit has held that the PREP Act does not provide federal courts jurisdiction over nursing home wrongful death claims. However, "the unique crisis presented by the COVID-19 pandemic, and the lack of clear information, resources, treatment options and guidance from public health authorities that was available at the time, may provide some help to nursing homes defending their care and treatment of residents in their charge."

By Eric M. Kraus and William P. Keefer

8 minute read

January 25, 2022 | New York Law Journal

The learned intermediary doctrine and federal preemption law would, in all probability, preclude a failure-to-warn claim based on a failure to provide mitigation instructions.

By Eric M. Kraus and Joshua Glasgow

8 minute read

May 18, 2009 | New York Law Journal

Eric M. Kraus, a partner at Sedgwick, Detert, Moran & Arnold, and Soo Y. Kim, a senior associate at the firm, discuss the courts' changing attitudes toward consideration of expert testimony in deciding whether to certify a class. A recent judicial pronouncement on this topic leaves no question that the courts will subject such testimony to a rigorous review in the class certification analysis, even where such testimony touches on "merits" issues.

By Eric M. Kraus and Soo Y. Kim

18 minute read

April 26, 2007 | New York Law Journal

Eric M. Kraus, a partner at Sedgwick, Detert, Moran & Arnold, and Eva Canaan, an associate at the firm, write that President George W. Bush recently signed into law the Dietary Supplement and Non-Prescription Drug Consumer Protection Act. Effective in one year, the act will require that manufacturers, packers or distributors of nonprescription drugs and dietary supplements to inform the Food and Drug Administration of any serious adverse event reports received.

By Eric M. Kraus and Eva Canaan

10 minute read

October 16, 2008 | New York Law Journal

Eric M. Kraus, a partner at Sedgwick, Detert, Moran & Arnold, writes that it is important to seriously consider the legal implications of internal policies, particularly with the proliferation of Internet-accessible corporate codes of conduct. Also in this issue of GC New York, "Class Action Communications" and "Super-Sized Law Firms."

By Eric M. Kraus

16 minute read